Comprehensive Pneumology Center, Ludwig-Maximilians-Universität, University Hospital Grosshadern and Helmholtz Zentrum München and Member of the German Center for Lung Research, Munich, Germany.
Division of Respiratory Sciences and Critical Care Medicine, Dept of Medicine, University of Colorado, Denver, CO, USA.
Eur Respir Rev. 2017 Sep 27;26(145). doi: 10.1183/16000617.0021-2017. Print 2017 Sep 30.
Fibrotic lung diseases involve subject-environment interactions, together with dysregulated homeostatic processes, impaired DNA repair and distorted immune functions. Systems medicine-based approaches are used to analyse diseases in a holistic manner, by integrating systems biology platforms along with clinical parameters, for the purpose of understanding disease origin, progression, exacerbation and remission.Interstitial lung diseases (ILDs) refer to a heterogeneous group of complex fibrotic diseases. The increase of systems medicine-based approaches in the understanding of ILDs provides exceptional advantages by improving diagnostics, unravelling phenotypical differences, and stratifying patient populations by predictable outcomes and personalised treatments. This review discusses the state-of-the-art contributions of systems medicine-based approaches in ILDs over the past 5 years.
纤维化肺疾病涉及宿主-环境相互作用，以及失调的内稳态过程、受损的 DNA 修复和紊乱的免疫功能。基于系统医学的方法用于全面分析疾病，通过整合系统生物学平台以及临床参数，以了解疾病的起源、进展、恶化和缓解。间质性肺疾病（ILDs）是指一组异质性的复杂纤维化疾病。基于系统医学的方法在ILDs 中的应用增加，通过提高诊断能力、揭示表型差异以及通过可预测的结果和个体化治疗对患者人群进行分层，提供了卓越的优势。这篇综述讨论了过去 5 年来基于系统医学的方法在 ILDs 中的最新进展。
